ArticleMolecular biotechnology2026
Optimization of Human STARD3 Cholesterol Transporter Expression for Enhancing Bovine P450scc-Mediated Steroid Biotransformation in E. coli.
Article in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This study investigates the optimization of human STARD3 cholesterol transporter expression to enhance bovine P450scc-mediated steroid biotransformation in Escherichia coli, co-expressing STARD3 and P450scc system proteins (cytochrome P450scc (CYP11A1), adrenodoxin and adrenodoxin reductase). We compared different expression strategies for STARD3, including the use of pelB and TorA signal peptides for potential periplasmic localization, and evaluated different E. coli strains to maximize cholesterol biotransformation. Although both signal peptides failed to efficiently transport STARD3 to the periplasm, with most of the protein remaining in the cytoplasm and membrane fractions, the STARD3 protein retained functionality in cholesterol transport. Auto-induction with lactose proved superior to IPTG-based induction, resulting in significantly higher expression levels of both STARD3 and P450scc. Among the E. coli strains tested (BL21(DE3), BL21(DE3)pLysS, HMS174(DE3), C41(DE3), and Rosetta(DE3)pLysS), Rosetta(DE3)pLysS demonstrated the highest STARD3 expression and the most significant impact of STARD3 on cholesterol biotransformation. It increased P450scc activity by approximately three times in Rosetta(DE3)pLysS compared to strains expressing only the P450scc system proteins. This strain showed a cholesterol biotransformation efficiency that was 6.97 ± 3.69 times higher compared to the previously used BL21(DE3). These results provide valuable insights for the optimization of recombinant steroidogenic systems in bacterial hosts for potential biotechnological applications.
Indexed as
Identifiers
40844562What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.